Search research articles
Contact Us
Filters
Showing results (21-30 of 144) with videos related to
Page
of 15
Sort By:
The New England Journal of Medicine
|
August 16, 2018
Rationale, Opportunities, and Reality of Biosimilar Medications
Gary H Lyman, Robin Zon, R Donald Harvey
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
August 1, 2018
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma
Donald C Moore, Justin R Arnall, R Donald Harvey
Cancer
|
February 13, 2019
Reply to Tumor-associated macrophages: "Good cop-bad cop"
Mehmet Asim Bilen, Haydn T Kissick, R Donald Harvey
Cardiovascular & Hematological Agents in Medicinal Chemistry
|
November 1, 2006
Novel therapeutic agents in the management of hemorrhage and thrombosis
Christine L Kempton, R Donald Harvey, Harold R Roberts
The Oncologist
|
March 24, 2020
In Reply
Mehmet Asim Bilen, Viraj A Master, R Donald Harvey
Journal of the Advanced Practitioner in Oncology
|
June 6, 2022
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective
R Donald Harvey, Aaron Begue, Caleb Raine, et al.
Oncology (Williston Park, N.Y.)
|
April 17, 2010
Through the looking glass: the evolution of erythropoiesis-stimulating agent use
R Donald Harvey, Fadlo R Khuri, John S Kauh
Expert Review of Anticancer Therapy
|
September 24, 2020
Current developments in the combination therapy of relapsed/refractory multiple myeloma
Kathryn T Maples, Nisha S Joseph, R Donald Harvey
Therapeutic Advances in Medical Oncology
|
January 2, 2014
Taxanes: vesicants, irritants, or just irritating?
Meagan S Barbee, Taofeek K Owonikoko, R Donald Harvey
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
June 23, 2020
Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings
R Donald Harvey, Val R Adams, Tyler Beardslee, et al.
Page
of 15
Search research articles
Search
Showing results (21-30 of 144) with videos related to
Sort By:
Page
of 15
The New England Journal of Medicine
|
August 16, 2018
Rationale, Opportunities, and Reality of Biosimilar Medications
Gary H Lyman, Robin Zon, R Donald Harvey
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
August 1, 2018
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma
Donald C Moore, Justin R Arnall, R Donald Harvey
Cancer
|
February 13, 2019
Reply to Tumor-associated macrophages: "Good cop-bad cop"
Mehmet Asim Bilen, Haydn T Kissick, R Donald Harvey
Cardiovascular & Hematological Agents in Medicinal Chemistry
|
November 1, 2006
Novel therapeutic agents in the management of hemorrhage and thrombosis
Christine L Kempton, R Donald Harvey, Harold R Roberts
The Oncologist
|
March 24, 2020
In Reply
Mehmet Asim Bilen, Viraj A Master, R Donald Harvey
Journal of the Advanced Practitioner in Oncology
|
June 6, 2022
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective
R Donald Harvey, Aaron Begue, Caleb Raine, et al.
Oncology (Williston Park, N.Y.)
|
April 17, 2010
Through the looking glass: the evolution of erythropoiesis-stimulating agent use
R Donald Harvey, Fadlo R Khuri, John S Kauh
Expert Review of Anticancer Therapy
|
September 24, 2020
Current developments in the combination therapy of relapsed/refractory multiple myeloma
Kathryn T Maples, Nisha S Joseph, R Donald Harvey
Therapeutic Advances in Medical Oncology
|
January 2, 2014
Taxanes: vesicants, irritants, or just irritating?
Meagan S Barbee, Taofeek K Owonikoko, R Donald Harvey
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
June 23, 2020
Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings
R Donald Harvey, Val R Adams, Tyler Beardslee, et al.
Page
of 15